14 research outputs found
Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors
Funding: RTM is supported by a Wellcome Trust Intermediate Clinical Fellowship (grant no: 098522), https://wellcome.ac.uk/what-we-do/directories/intermediate-clinical-fellowships-people-funded. TWK is supported by Engineering and Physical Sciences Research Council grant EP/P015638/1, http://gow.epsrc.ac.uk/NGBOViewGrant.aspx?GrantRef=EP/P015638/1.The accuracy of Follicle Stimulating Hormone as a predictor of azoospermia in adult survivors of childhood cancer is unclear, with conflicting results in the published literature. A systematic review and post hoc analysis of combined data (n = 367) were performed on all published studies containing extractable data on both serum Follicle Stimulating Hormone concentration and semen concentration in survivors of childhood cancer. PubMed and Medline databases were searched up to March 2017 by two blind investigators. Articles were included if they contained both serum FSH concentration and semen concentration, used World Health Organisation certified methods for semen analysis, and the study participants were all childhood cancer survivors. There was no evidence for either publication bias or heterogeneity for the five studies. For the combined data (n = 367) the optimal Follicle Stimulating Hormone threshold was 10.4 IU/L with specificity 81% (95% CI 76%–86%) and sensitivity 83% (95% CI 76%–89%). The AUC was 0.89 (95%CI 0.86–0.93). A range of threshold FSH values for the diagnosis of azoospermia with their associated sensitivities and specificities were calculated. This study provides strong supporting evidence for the use of serum Follicle Stimulating Hormone as a surrogate biomarker for azoospermia in adult males who have been treated for childhood cancer.Publisher PDFPeer reviewe
A Review of the Alleged Health Hazards of Monosodium Glutamate
Monosodium glutamate (MSG) is an umami substance widely used as flavor enhancer. Although it is generally recognized as being safe by food safety regulatory agencies, several studies have questioned its long-term safety. The purpose of this review was to survey the available literature on preclinical studies and clinical trials regarding the alleged adverse effects of MSG. Here, we aim to provide a comprehensive overview of the reported possible risks that may potentially arise following chronic exposure. Preclinical studies have associated MSG administration with cardiotoxicity, hepatotoxicity, neurotoxicity, low-grade inflammation, metabolic disarray, and premalignant alterations, along with behavioral changes. However, in reviewing the available literature, we detected several methodological flaws, which led us to conclude that these studies have limited relevance for extrapolation to dietary human intake of MSG risk exposure. Clinical trials have focused mainly on MSG effects on food intake and energy expenditure. Besides its well-known impact on food palatability, MSG enhances salivary secretion and interferes with carbohydrate metabolism, while the impact on satiety and post-meal recovery of hunger varied in relation to meal composition. Reports on MSG hypersensitivity or links of its use to increased pain sensitivity and atopic dermatitis were found to have little supporting evidence. Many of the reported negative health effects of MSG have little relevance for chronic human exposure and are poorly informative as they are based on excessive dosing that does not meet with levels normally consumed in food products. We conclude that further clinical and epidemiological studies are needed, with an appropriate design, accounting for both added and naturally occurring dietary MSG. © 2019 Institute of Food Technologists
Prevention of HIV infection transmission from mother to child in Romania - a simultaneous objective and challenge
Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors
The accuracy of Follicle Stimulating Hormone as a predictor of azoospermia in adult survivors of childhood cancer is unclear, with conflicting results in the published literature. A systematic review and post hoc analysis of combined data (n = 367) were performed on all published studies containing extractable data on both serum Follicle Stimulating Hormone concentration and semen concentration in survivors of childhood cancer. PubMed and Medline databases were searched up to March 2017 by two blind investigators. Articles were included if they contained both serum FSH concentration and semen concentration, used World Health Organisation certified methods for semen analysis, and the study participants were all childhood cancer survivors. There was no evidence for either publication bias or heterogeneity for the five studies. For the combined data (n = 367) the optimal Follicle Stimulating Hormone threshold was 10.4 IU/L with specificity 81% (95% CI 76%–86%) and sensitivity 83% (95% CI 76%–89%). The AUC was 0.89 (95%CI 0.86–0.93). A range of threshold FSH values for the diagnosis of azoospermia with their associated sensitivities and specificities were calculated. This study provides strong supporting evidence for the use of serum Follicle Stimulating Hormone as a surrogate biomarker for azoospermia in adult males who have been treated for childhood cancer
Overview of the effects of chemical mixtures with endocrine disrupting activity in the context of real-life risk simulation (RLRS):An integrative approach (Review)
Sensitivity and specificity of FSH-based azoospermia diagnosis for a range of threshold values.
<p>Median and 95% CI are calculated from 2,000 stratified bootstrap replicates of the combined data (n = 367).</p
Receiver-operator characteristic (ROC) curve analysis of FSH as predictor of azoospermia (combined cohort: n = 367).
<p>Area under the curve: 0·89 (95% CI 0·85–0·92. The optimal diagnostic threshold is 10.4 mIU/mL, with sensitivity 0.814 and specificity 0.823.</p
Flow-chart of systematic search methodology.
<p>n = number of studies; N = number of childhood cancer survivors fulfilling criteria.</p
Forest plot of 95% confidence limits for the log-adjusted diagnostic odds ratio for the five studies listed in Table 1.
<p>The vertical dashed line denotes the line of no effect. Visual inspection shows that each study is statistically significant in its own right, that the intervals overlap to a great extent, and that therefore the studies are unlikely to be heterogeneous.</p
Funnel plots for specificity (upper panel) and sensitivity (lower panel) relating study size to reported diagnostic accuracy for the five studies listed in Table 1.
<p>The Chi-squared statistical test for funnel plot asymmetry did not reach statistical significance (p = 0.32 for sensitivity; p = 0.17 for specificity), suggesting a lack of publication bias.</p